Molecular Pathology Special Interest Track-Current Advances in Melanoma and Brain Metastases
Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis
Monday, August 29, 2022 at 1:00pm EDT-2:00pm ET
The Society for Neuro-Oncology and the Molecular Pathology Special Interest Track are pleased to announce the quarterly event for the SNO Pathology FAST (First Author Series Talk) webinar series.
Registration is free and limited to the first 1,000 participants. All SNO webinars are recorded, so if you miss one, you will be able to view it on-demand in the Neuro-Oncology Academy.
Kevin Kleffman, MD, PhD – Massachusetts General Hospital
Eva Hernando-Monge, PhD – NYU Langone
Adrienne Boire, MD, PhD – Memorial Sloan Kettering
Molecular Pathology Special Interest Track Chairs:
Stephen Yip, MD, PhD – Vancouver General Hospital
Sandro Santagata, MD, PhD – Harvard Medical School
Jason Huse, MD, PhD – MD Anderson Cancer Center
- Melanoma-secreted amyloid beta is specifically required for growth and survival of melanoma cells in the brain parenchyma.
- Melanoma-secreted amyloid beta suppresses inflammatory gene expression in astrocytes and protects against microglial phagocytosis
- Amyloid beta is a promising therapeutic target for treatment of melanoma brain metastasis.
Neuro-Oncologists, Neuropathologists, Neurosurgeons, and Basic and Translational researchers studying brain tumors.
We hope that you are able to participate in this upcoming webinar. If you have ideas or topics that you would like for us to consider for future webinars, please email email@example.com
, or complete the online form.